Quarterly report pursuant to Section 13 or 15(d)

STOCK OPTIONS AND WARRANTS

v3.21.2
STOCK OPTIONS AND WARRANTS
9 Months Ended
Sep. 30, 2021
STOCK OPTIONS AND WARRANTS  
NOTE 16 - STOCK OPTIONS AND WARRANTS

NOTE 16 - STOCK OPTIONS AND WARRANTS

 

Options

 

On November 13, 2014, our Board of Directors authorized and approved the adoption of the Plan effective November 13, 2014 (2014 Stock Option Plan) under which an aggregate of 20% (290,879 shares) of the issued and outstanding shares may be issued. The plan shall terminate ten years after the plan's adoption by the board of directors. We granted an aggregate 145,000 stock options. As of September 30, 2021, an aggregate total of 145,879 can still be granted under the plan.

 

On June 15, 2016, our board of Directors authorized and approved the adoption of the Equity Incentive Plan effective June 15, 2016 (2016 Equity Incentive Plan) under which an aggregate of 656,250 shares may be issued. The plan shall terminate ten years after the plan's adoption by the board of directors. We granted an aggregate of 330,350 stock options. As of September 30, 2021 an aggregate total of 325,900 options can still be granted under the plan.

On May 15, 2018, the Board of Directors approved and adopted the BioCorRx Inc. 2018 Equity Incentive Plan (2018 Stock Option Plan) under which an aggregate of 450,000 shares may be issued. The plan shall terminate ten years after the plan's adoption by the board of directors. The Company has granted an aggregate of 363,281 stock options. As of September 30, 2021 an aggregate total of 86,719 options can still be granted under the plan.

 

No options were granted during the nine months ended September 30, 2021.

 

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from using the Company's historical stock prices. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the "simplified" method, which is used for "plain-vanilla" options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

 

In applying the Black-Scholes option pricing model, the Company used the following assumptions in 2020:

 

Risk-free interest rate

 

0.27% - 0.29%

 

Expected term (years)

 

3.00 - 5.00

 

Expected volatility

 

112.97% - 137.27%

 

Expected dividends

 

 

0.00

 

 

The following table summarizes the stock option activity for the nine months ended September 30, 2021:

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Weighted-

 

 

Remaining

 

 

Aggregate

 

 

 

 

 

Average

 

 

Contractual

 

 

Intrinsic

 

 

 

Shares

 

 

Exercise Price

 

 

Term

 

 

Value

 

Outstanding at December 31, 2020

 

 

828,631

 

 

$ 7.84

 

 

 

5.8

 

 

$ -

 

Expired

 

 

(10,000 )

 

 

7.49

 

 

 

-

 

 

 

-

 

Outstanding at September 30, 2021

 

 

818,631

 

 

$ 7.85

 

 

 

5.1

 

 

$ 615,099

 

Exercisable at September 30, 2021

 

 

818,006

 

 

$ 7.85

 

 

 

5.1

 

 

$ 613,968

 

 

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company's stock price of $3.81 as of September 30, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.

 

The following table presents information related to stock options at September 30, 2021:

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

 

 

Weighted

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

Exercisable

 

 

Average

 

 

Exercise

 

Number of

 

 

Remaining Life

 

 

Number of

 

 

Remaining Life

 

 

Price

 

Options

 

 

In Years

 

 

Options

 

 

In Years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

0.01-2.50

 

 

337,850

 

 

 

4.7

 

 

 

337,225

 

 

 

4.7

 

 

2.51-5.00

 

 

43,334

 

 

 

3.4

 

 

 

43,334

 

 

 

3.4

 

 

5.01 and up

 

 

437,447

 

 

 

5.7

 

 

 

437,447

 

 

 

5.7

 

 

 

 

 

818,631

 

 

 

5.1

 

 

 

818,006

 

 

 

5.1

 

 

The stock-based compensation expense related to option grants was $0 and $8,715 during the three and nine months ended September 30, 2021 and $7,827 and $65,797 during the three and nine months ended September 30, 2020, respectively.

 

Warrants

 

The outstanding Warrants contain provisions, often referred to as "down-round protection" that has led to adjustments of the exercise price and number of underlying warrant shares with respect to future issuances by the Company of its securities, including its common stock or convertible securities or debt securities.

The following table summarizes the changes in warrants outstanding and the related prices for the shares of the Company's common stock:

 

Warrants Outstanding

 

 

Warrants Exercisable

 

Exercise Prices

 

 

Number

Outstanding

 

 

Weighted

Average

Remaining

Contractual

Life

(Years)

 

 

Weighted

Average

Exercise

Price

 

 

Number

Exercisable

 

 

Weighted

Average

Remaining

Contractual

Life (Years)

 

$

20.00

 

 

 

10,000

 

 

 

0.2

 

 

$ 20.00

 

 

 

10,000

 

 

 

0.2

 

$

100.00

 

 

 

5,000

 

 

 

0.0

 

 

 

100.00

 

 

 

5,000

 

 

 

0.0

 

$

-

 

 

 

15,000

 

 

 

0.1

 

 

$ 46.67

 

 

 

15,000

 

 

 

0.1

 

 

The following table summarizes the warrant activity for the three months ended September 30, 2021:

 

 

 

Number of

Shares

 

 

Weighted

Average

Exercise

Price Per

Share

 

Outstanding at December 31, 2020

 

 

72,500

 

 

$ 89.00

 

Issued

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

Expired

 

 

(57,500 )

 

 

100.00

 

Outstanding at September 30, 2021

 

 

15,000

 

 

$ 46.67